Agile Therapeutics Inc.

0.6415+0.0070+1.10%Vol 4.10M1Y Perf -42.32%
Aug 11th, 2022 16:00 DELAYED
BID0.6330 ASK0.6445
Open0.6435 Previous Close0.6345
Pre-Market- After-Market0.62
 - -  -0.02 -3.35%
Target Price
95.00 
Analyst Rating
Strong Buy 1.00
Potential %
14.71K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
     21.82
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.31 
Earnings Rating
Buy
Market Cap20.21M 
Earnings Date
11th Aug 2022
Alpha-0.03 Standard Deviation0.33
Beta1.61 

Today's Price Range

0.63000.6700

52W Range

0.485150.40

5 Year PE Ratio Range

-3.50-4.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
7.65%
1 Month
-4.05%
3 Months
-61.12%
6 Months
103.59%
1 Year
-42.32%
3 Years
-43.23%
5 Years
-80.56%
10 Years
-

TickerPriceChg.Chg.%
AGRX0.64150.00701.10
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-92.90
-1 224.30
-1 184.80
-
-
RevenueValueIndustryS&P 500US Markets
4.56M
0.14
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022--3.78-
Q04 2021-6.80-8.00-17.65
Q03 2021-7.60-7.205.26
Q02 2021-8.40-8.004.76
Q01 2021-8.80-8.009.09
Q04 2020-9.20-8.0013.04
Q03 2020-0.18-0.180.00
Q02 2020-0.13-0.127.69
Earnings Per EndEstimateRevision %Trend
3/2022 QR-4.800.00-
6/2022 QR-4.009.09Positive
12/2022 FY-2.1945.25Positive
12/2023 FY-0.4090.00Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume4.10M
Shares Outstanding31.51K
Shares Float31.51M
Trades Count4.48K
Dollar Volume2.65M
Avg. Volume8.30M
Avg. Weekly Volume7.62M
Avg. Monthly Volume6.93M
Avg. Quarterly Volume10.35M

Agile Therapeutics Inc. (NASDAQ: AGRX) stock closed at 0.6415 per share at the end of the most recent trading day (a 1.1% change compared to the prior day closing price) with a volume of 4.10M shares and market capitalization of 20.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 15 people. Agile Therapeutics Inc. CEO is Alfred Altomari.

The one-year performance of Agile Therapeutics Inc. stock is -42.32%, while year-to-date (YTD) performance is 31.43%. AGRX stock has a five-year performance of -80.56%. Its 52-week range is between 0.4851 and 50.4, which gives AGRX stock a 52-week price range ratio of 0.31%

Agile Therapeutics Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 9.38, a price-to-sale (PS) ratio of 3.87, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -162.73%, a ROC of -199.51% and a ROE of -397.83%. The company’s profit margin is -%, its EBITDA margin is -1 184.80%, and its revenue ttm is $4.56 Million , which makes it $0.14 revenue per share.

Of the last four earnings reports from Agile Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Agile Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Agile Therapeutics Inc. is Strong Buy (1), with a target price of $95, which is +14 709.00% compared to the current price. The earnings rating for Agile Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Agile Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Agile Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.46, ATR14 : 0.10, CCI20 : 129.90, Chaikin Money Flow : 0.01, MACD : -0.06, Money Flow Index : 69.25, ROC : 18.80, RSI : 39.35, STOCH (14,3) : 54.90, STOCH RSI : 0.82, UO : 55.63, Williams %R : -45.10), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Agile Therapeutics Inc. in the last 12-months were: Alfred Altomari (Buy at a value of $0), Dennis P. Reilly (Buy at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Moderate Buy
2.00
Moderate Buy
2.00

Agile Therapeutics Inc.

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.

CEO: Alfred Altomari

Telephone: +1 609 683-1880

Address: 101 Poor Farm Road, Princeton 08540, NJ, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

64%36%

Bearish Bullish

62%38%

TipRanks News for AGRX

Mon, 11 Jul 2022 11:55 GMT Agile Therapeutics (AGRX) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Thu, 05 May 2022 17:55 GMT Agile Therapeutics (AGRX) Gets a Hold Rating from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits